SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 813.62+0.2%12:49 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (110)6/9/1997 9:17:00 AM
From: scaram(o)uche   of 3559
 
I also regard this as a positive. The remaining collaborative projects with Amgen will have a life of their own, but they will no longer have a strangle hold on REGN. If results look promising or even sort of "BDNF-like" after phase II and if AMGN wants to commit suicide on their own this time, then the "partners", AMGN and REGN can perhaps do a deal.

Fact is, Binder et al, can no longer drag this cash-rich company into their follies. REGN now has negotiating and breathing room, and the new allignment of R&D responsibilities will rejuvinate.

Elbow room, with the best management East of Icos.

Rick

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News